N-of-1 trials in cancer drug development
The current approaches for cancer drug development lag behind an accelerated need in the field for a fast and efficient method for evaluating drugs in the personalized medicine era. In that regard, N-of-1 studies emerge as a potential addition to the drug development arsenal, although there are seve...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
1 June 2023
|
| In: |
Cancer discovery
Year: 2023, Jahrgang: 13, Heft: 6, Pages: 1301-1309 |
| ISSN: | 2159-8290 |
| DOI: | 10.1158/2159-8290.CD-22-1377 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1158/2159-8290.CD-22-1377
|
| Verfasserangaben: | Mohamed A. Gouda, Lars Buschhorn, Andreas Schneeweiss, Adam Wahida, and Vivek Subbiah |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1853470376 | ||
| 003 | DE-627 | ||
| 005 | 20240307065521.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230724s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/2159-8290.CD-22-1377 |2 doi | |
| 035 | |a (DE-627)1853470376 | ||
| 035 | |a (DE-599)KXP1853470376 | ||
| 035 | |a (OCoLC)1425214398 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Gouda, Mohamed A. |e VerfasserIn |0 (DE-588)1297144147 |0 (DE-627)1853471232 |4 aut | |
| 245 | 1 | 0 | |a N-of-1 trials in cancer drug development |c Mohamed A. Gouda, Lars Buschhorn, Andreas Schneeweiss, Adam Wahida, and Vivek Subbiah |
| 264 | 1 | |c 1 June 2023 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 24.07.2023 | ||
| 520 | |a The current approaches for cancer drug development lag behind an accelerated need in the field for a fast and efficient method for evaluating drugs in the personalized medicine era. In that regard, N-of-1 studies emerge as a potential addition to the drug development arsenal, although there are several considerations before its broad application becomes feasible. In essence, N-of-1 trials are a departure from the traditional “drug-centric” model to a “patient-centric” model. Herein, we review the concept of N-of-1 trials and provide real-world examples of their use in the developmental therapeutics field. N-of-1 trials offer an exceptional opportunity for fast-tracking of cancer drug development in the precision oncology era. | ||
| 700 | 1 | |a Buschhorn, Lars |e VerfasserIn |0 (DE-588)1278897372 |0 (DE-627)1831786680 |4 aut | |
| 700 | 1 | |a Schneeweiss, Andreas |d 1961- |e VerfasserIn |0 (DE-588)109972554 |0 (DE-627)632849630 |0 (DE-576)327251859 |4 aut | |
| 700 | 1 | |a Wahida, Adam |e VerfasserIn |4 aut | |
| 700 | 1 | |a Subbiah, Vivek |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer discovery |d Philadelphia, Pa. : [Verlag nicht ermittelbar], 2011 |g 13(2023), 6 vom: Juni, Seite 1301-1309 |h Online-Ressource |w (DE-627)659209411 |w (DE-600)2607892-2 |w (DE-576)347274315 |x 2159-8290 |7 nnas |a N-of-1 trials in cancer drug development |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g number:6 |g month:06 |g pages:1301-1309 |g extent:9 |a N-of-1 trials in cancer drug development |
| 856 | 4 | 0 | |u https://doi.org/10.1158/2159-8290.CD-22-1377 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230724 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 109972554 |a Schneeweiss, Andreas |m 109972554:Schneeweiss, Andreas |d 910000 |d 910400 |d 50000 |e 910000PS109972554 |e 910400PS109972554 |e 50000PS109972554 |k 0/910000/ |k 1/910000/910400/ |k 0/50000/ |p 3 | ||
| 998 | |g 1278897372 |a Buschhorn, Lars |m 1278897372:Buschhorn, Lars |d 910000 |d 910100 |e 910000PB1278897372 |e 910100PB1278897372 |k 0/910000/ |k 1/910000/910100/ |p 2 | ||
| 999 | |a KXP-PPN1853470376 |e 4357153891 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"name":{"displayForm":["Mohamed A. Gouda, Lars Buschhorn, Andreas Schneeweiss, Adam Wahida, and Vivek Subbiah"]},"note":["Gesehen am 24.07.2023"],"person":[{"given":"Mohamed A.","display":"Gouda, Mohamed A.","family":"Gouda","role":"aut"},{"family":"Buschhorn","role":"aut","given":"Lars","display":"Buschhorn, Lars"},{"display":"Schneeweiss, Andreas","given":"Andreas","family":"Schneeweiss","role":"aut"},{"given":"Adam","display":"Wahida, Adam","family":"Wahida","role":"aut"},{"family":"Subbiah","role":"aut","given":"Vivek","display":"Subbiah, Vivek"}],"recId":"1853470376","id":{"eki":["1853470376"],"doi":["10.1158/2159-8290.CD-22-1377"]},"physDesc":[{"extent":"9 S."}],"title":[{"title_sort":"N-of-1 trials in cancer drug development","title":"N-of-1 trials in cancer drug development"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"2023","dateIssuedDisp":"1 June 2023"}],"relHost":[{"part":{"text":"13(2023), 6 vom: Juni, Seite 1301-1309","issue":"6","extent":"9","pages":"1301-1309","volume":"13","year":"2023"},"language":["eng"],"note":["Gesehen am 08.06.2023","Fortsetzung der Druck-Ausgabe"],"pubHistory":["Volume 1, number 1 (June 2011)-"],"disp":"N-of-1 trials in cancer drug developmentCancer discovery","type":{"bibl":"periodical","media":"Online-Ressource"},"name":{"displayForm":["American Association for Cancer Research"]},"recId":"659209411","physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2607892-2"],"eki":["659209411"],"issn":["2159-8290"]},"title":[{"title_sort":"Cancer discovery","title":"Cancer discovery"}],"origin":[{"publisherPlace":"Philadelphia, Pa.","publisher":"[Verlag nicht ermittelbar]","dateIssuedDisp":"[2011]-"}]}]} | ||
| SRT | |a GOUDAMOHAMNOF1TRIALS1202 | ||